Download or read book Mergers and Acquisitions written by Mark Thomas and published by Taylor & Francis. This book was released on 2024-04-05 with total page 211 pages. Available in PDF, EPUB and Kindle. Book excerpt: Covid-19 has brought so much uncertainty, but one certainty is that the vaccine race will generate winners and losers in the pharmaceutical and biotechnology industries. This will have a major impact on merger and acquisition activity. While the plethora of merger and acquisition deals are abundantly reported by the news media, there is a clear lack of in-depth analysis on the multiple rationales and various challenges in the life sciences industry. By offering contributions from a variety of experts in the biotechnology and pharmaceutical industries, as well as experts on mergers and acquisitions, this edited collection will draw upon the knowledge of a variety of different actors within the fields of pharma and biotech. This book offers a timely exploration of the complexities of mergers and acquisitions in the pharmaceutical and biotechnology industries while seeking to bridge the gap between theory and practice. It presents a critical analysis of the rationale for acquisitions and studies the challenges of ensuring a successful deal. In the light of the Covid-19 pandemic, it will also explore the impact this may have on the industry, which may further stimulate merger and acquisition activity. It will be of interest to researchers, academics, policymakers, and students in the fields of strategy, management, governance, and the biotechnology and pharmaceutical industries.

Download or read book Mergers and Acquisitions in Pharmaceuticals Why and How written by R. D. Neirinckx and published by Rudi Neirinckx. This book was released on 2000-02 with total page 201 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Mergers and Acquisitions in the Pharmaceutical and Biotech Industries written by John Mathias Ireland and published by . This book was released on 1998 with total page 356 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Biotechnology Deals written by and published by . This book was released on 2005 with total page 148 pages. Available in PDF, EPUB and Kindle. Book excerpt: Inside the Minds: Biotechnology Deals is an authoritative, insider's perspective on the issues surrounding biotech deals, including mergers and acquisitions, collaborations, and the future of doing successful deals. Featuring lawyers, CEOs of funded biotech companies, and venture capitalists who invest in them, this book provides a broad, yet comprehensive overview of the art of doing successful deals from the experts themselves. From finding and capitalizing on opportunities to completing the deal, these authors articulate the finer points around doing biotech deals now and what will hold true into the future. The different niches represented and the breadth of perspectives presented enable readers to get inside some of the great legal minds of today as experts offer up their thoughts around the keys to success within this fascinating area.About Inside the Minds:Inside the Minds provides readers with proven business intelligence from C-Level executives (Chairman, CEO, CFO, CMO, Partner) from the world's most respected companies nationwide, rather than third-party accounts from unknown authors and analysts. Each chapter is comparable to an essay/thought leadership piece and is a future-oriented look at where an industry, profession or topic is headed and the most important issues for the future. Through an exhaustive selection process, each author was hand-picked by the Inside the Minds editorial board to author a chapter for this book.This book is by: Lee R. Brettman, M.D., FACP, Dynogen Pharmaceuticals, Inc.??Successful Strategies for Biotech Deals?Manish N Chapekar, Montreux Equity Partners??Building Successful Biotech Deals?Daniel Devine, Acceptys, Inc.??The Art of the Deal?Mark I. Gruhin, Schmeltzer, Aptaker & Shepard, PC??Mergers and Acquisitions, Collaborations, and Partnerships?James T. Gunton, NJTC Venture Fund??Strategies for Successful Deals?Johnny Humphreys, Gen Prime??Finding Success in Biotech?Roland H. Johnson, Piedmont Pharmaceuticals LLC??Making Your Way Through Biotech Dealings?Thomas G. Klopack, Self Employed, Former CEO of Aclara Biosciences??Keys to Success in Biotechnology?Gerard J. McGarrity, Ph.D., Intronn Inc.??Successful Biotech Deals?Mark Schwartz , Ph.D., Bayhill Therapeutics??Biotech Deal Strategies?Abhi-Shek Jain, WTP Capital, LLC??Secrets to Success?Alexis V. Lukianov, NuVasive, Inc.??Finding and Capitalizing on Opportunities?

Download or read book Mergers and Acquisitions in the Pharmaceutical and Biotech Industries written by Patricia M. Danzon and published by . This book was released on 2012 with total page 43 pages. Available in PDF, EPUB and Kindle. Book excerpt: This paper examines the determinants of Mamp;A in the pharmaceutical-biotechnology industry and the effects of mergers using propensity scores to control for endogeneity. Among large firms, we find that mergers are a response to excess capacity due to anticipated patent expirations and gaps in a company's product pipeline. For small firms, mergers are primarily an exit strategy for firms in financial trouble, as indicated by low Tobin's q, few marketed products, and low cash-sales ratios. Conversely, small firms with a relatively high Tobin's q, a large number of marketed products, and high cash/sales ratios are less likely to engage in any Mamp;A activity.We find that it is important to control for a firm's prior propensity to merge. Firms with relatively high propensity scores experienced slower growth of sales, employees and Ramp;D regardless of whether they actually merged, which is consistent with mergers being a response to distress. Controlling for a firm's merger propensity, large firms that merged experienced similar changes in enterprise value, sales, employees, and Ramp;D relative to similar firms that did not merge. Merged firms had slower growth in operating profit growth in the third year following a merger. Thus mergers may be a response to trouble, but they are not an effective solution for large firms. Neither mergers nor propensity scores have any effect on subsequent growth in enterprise value. This confirms that market valuations on average yield unbiased predictions of the effects of mergers. Small firms that merged experienced slower Ramp;D growth relative to similar firms that did not merge, suggesting that post-merger integration may divert cash from Ramp;D.

Download or read book Mergers and Acquisitions in the Pharmaceutical and Biotech Industries written by Patricia Munch Danzon and published by . This book was released on 2004 with total page 35 pages. Available in PDF, EPUB and Kindle. Book excerpt: This paper examines the determinants of M&A activity in the pharmaceutical-biotechnology industry and the effects of mergers using propensity scores to control for merger endogeneity. Among large firms, we find that mergers are a response to excess capacity due to anticipated patent expirations and gaps in a company's product pipeline. For small firms, mergers are primarily an exit strategy for firms in financial trouble, as indicated by low Tobin's q, few marketed products, and low cash-sales ratios. We find that it is important to control for a firm's prior propensity to merge. Firms with relatively high propensity scores experienced slower growth of sales, employees and R&D regardless of whether they actually merged, which is consistent with mergers being a response to distress. Controlling for a firm's merger propensity, large firms that merged experienced similar changes in enterprise value, sales, employees, and R&D relative to similar firms that did not merge. Merged firms had slower growth in operating profit in the third year following a merger. Thus mergers may be a response to trouble, but they are not an effective solution for large firms. Neither mergers nor propensity scores have any effect on subsequent growth in enterprise value. This confirms that market valuations on average yield unbiased predictions of the effects of mergers. Small firms that merged experienced slower R&D growth relative to similar firms that did not merge, suggesting that post-merger integration may divert cash from R&D.

Download or read book Business Development for the Biotechnology and Pharmaceutical Industry written by Martin Austin and published by CRC Press. This book was released on 2016-04-08 with total page 202 pages. Available in PDF, EPUB and Kindle. Book excerpt: Business Development in the biotechnology and pharmaceutical industries accounts for over $5 billion in licensing deal value per year and much more than that in the value of mergers and acquisitions. Transactions range from licences to patented academic research, to product developments as licences, joint ventures and acquisition of intellectual property rights, and on to collaborations in development and marketing, locally or across the globe. Asset sales, mergers and corporate takeovers are also a part of the business development remit. The scope of the job can be immense, spanning the life-cycle of products from the earliest levels of research to the disposal of residual marketing rights, involving legal regulatory manufacturing, clinical development, sales and marketing and financial aspects. The knowledge and skills required of practitioners must be similarly broad, yet the availability of information for developing a career in business development is sparse. Martin Austin's highly practical guide spans the complete process and is based on his 30 years of experience in the industry and the well-established training programme that he has developed and delivers to pharmaceutical executives from across the world.

Download or read book Mergers and Acquisitions in the Global Pharmaceutical Industry written by Mennen and published by GRIN Verlag. This book was released on 2010-12-17 with total page 30 pages. Available in PDF, EPUB and Kindle. Book excerpt: Project Report from the year 2006 in the subject Communications - Public Relations, Advertising, Marketing, Social Media, grade: 65 % - B, University of Sunderland, course: Global Corporate Strategy, language: English, abstract: Mergers and acquisitions are of major importance in the pharmaceutical industry. In order to evaluate the dynamics of this particular industry, this paper critically evaluates the pre- and post- merger situation of GlaxoSmithKline concerning its ready-access to markets, know-how and management capability. Furthermore, strengths and weaknesses and merger’s outcomes will be outlined. Critical push and pull factors affecting M&A activity in North America will be analysed, using Pfizer and Pharmacia as an example. In addition, general reasons for M&A failure in the pharmaceutical industry will be illustrated focussing on the M&A activity of GlaxoSmithKline. Finally, using two global pharmaceutical players (GSK and Astrazeneca), the merits and demerits of the McKinsey’s five step programme will be discussed.

Download or read book Mergers Acquisitions in the Contract Research Organization Industry written by Jakob Miera and published by GRIN Verlag. This book was released on 2013-10-10 with total page 92 pages. Available in PDF, EPUB and Kindle. Book excerpt: Master's Thesis from the year 2013 in the subject Business economics - Business Management, Corporate Governance, grade: 1,0, , language: English, abstract: This thesis deals in general with mergers & acquisitions in the CRO industry, and more specifically with reasons for M&A, success factors during the M&A process, and why M&A can fail in the Contract Research Organization industry. The pharmaceutical industry faces increasing obstacles in respect to the development and introduction of new medications. That has to do with stricter requirements for admission and sharper controls by authorities. Today, the research and development of a new drug can easily consume more than $800 million and lasting between 10 and 15 years. Due to these admission, money and time pressures, pharmaceutical companies are looking for an alternative in the drug development process. A very popular alternative is the outsourcing or in-house working with Contract Research Organizations (CRO). Contract Research Organizations are specialized in coordination and monitoring of drug development activities. Due to their focus they often offer a more sophisticated and faster process. Demographic changes, chronic diseases like cancer and diabetes, and completely new cluster of symptoms demand new therapeutically treatments. The size of the CRO market in 2012 was around $32 billion and had an estimated market growth of around 9 – 12% for 2013. Increased outsourcing and allocation of R&D money towards CRO reflects a driving force for prospective growth. To benefit from the good industry outlooks CROs adjust their service offerings and strengthen their competitive situation. More and more Contract Research Organizations consider mergers & acquisitions as a vital solution to achieve their objectives. Since couple of years we can observe an increased number of deals. Large corporations can close the gaps in the internal service pipeline and smaller firms can use mergers as a financial exit. However, many M&A activities are considered as ineffective and contra-productive for the shareholder value – either destroy or merely add. Depending on the study, the numbers of M&A failures vary from 50% to even 80%. Possible reasons may be not enough integration planning and unrealistic expectations on the cost and time. The reality shows that it is not that easy to cut costs by simple combining two departments after a merger or acquisition. Additionally, we can see that mergers and acquisitions basically not succeed during the actual process.[...]

Download or read book The merger of sanofi aventis as an example for Reasons and Consequences of Mergers and Acquistions in the Pharmaceutical Industry written by Martin Wenderoth and published by GRIN Verlag. This book was released on 2009-02-13 with total page 19 pages. Available in PDF, EPUB and Kindle. Book excerpt: Essay from the year 2008 in the subject Business economics - Offline Marketing and Online Marketing, grade: (4) good, Eötvös Loránd Tudományegytem (International PhD Program), course: Business Economics, language: English, abstract: Within the ongoing globalisation process, many national markets and industrial branches are in different phases of the transition from local to global economic structures (Bryan, L.; Fraser, J.; Oppenheim, J. Rall, W., 2000, pp. 71-95). As a result of this development organisations in the different industries are increasingly concentrating (Brühl, V., 2003, pp. 274-278). Among other industries, also the pharmaceutical industry is highly influenced by the above mentioned trend, reflected by the increasing number of mergers and acquisitions (M&A’s) in the pharmaceutical industry, which is illustrated in the following figure. Figure 1: The present assignment is going to evaluate the reasons and consequences of M&A’s within the pharmaceutical industry by using the sanofi-aventis merger as an example. First of all, the recent history of sanofi-aventis is briefly described. The third part will describe the reasons and consequences of mergers and acquisitions in the pharmaceutical industry by describing the challenges the pharmaceutical branch is confronted with and the respective motives of and results from M&A activities. Finally, the major findings are summarised and conclusions will be derived. 2. History of sanofi-aventis Following the company homepage of sanofi-aventis (20071), the year 1999 has been very im-portant because of two reasons. First of all, Sanofi took over the Synthelabo Holding GmbH and changed its company name to Sanofi-Synthelabo. Furthermore, Hoechst merged with Rhône-Poulenc, a French chemical and pharmaceutical organisation in order to form the new company Aventis, with its legal seat in Strassbourgh (...)

Download or read book Consolidation and Innovation in the Pharmaceutical Industry written by Joanna Shepherd and published by . This book was released on 2017 with total page 26 pages. Available in PDF, EPUB and Kindle. Book excerpt: Recent changes in the pharmaceutical industry have spurred an unprecedented wave of mergers and acquisitions. Some researchers and agencies have questioned whether pharmaceutical consolidation could impede drug innovation. However, as I explain in this Article, these concerns are largely based on an outdated understanding of the drug innovation ecosystem. Whereas a few decades ago almost all drug discovery took place inside traditional pharmaceutical companies, today most drug innovation is externally-sourced from biotech companies and smaller firms. Internal R&D is no longer the primary source, or even an important source, of drug innovation. As a result, analyses that focus on the impacts of pharmaceutical consolidation on internal drug innovation are incomplete and missing the point. Instead, merger analyses should examine whether consolidation increases demand for externally-sourced innovation and, ultimately, strengthens aggregate drug innovation.

Download or read book Health Care Mergers and Acquisitions Answer Book written by Andrew L. Bab and published by . This book was released on 2016-10-07 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: M&A activity in the health care industry is at its highest level since the 1980s. Organized into four parts, this guide includes practical advice on how to address the various industry-specific issues arising in health care acquisitions.

Download or read book 1992 Planning for Chemicals Pharmaceuticals and Biotechnology written by Eurofi Plc and published by Elsevier. This book was released on 2013-10-22 with total page 412 pages. Available in PDF, EPUB and Kindle. Book excerpt: 1992-Planning for Chemicals, Pharmaceuticals and Biotechnology provides a summary of the relevant legislation, research programs, and proposals for the establishment of a single European market for the chemical, pharmaceutical, and biotechnology industries. The development of the European Community's (EC) policy and the implications of its implementation for the EC and third country markets are discussed. The views from a number of major organizations that operate in the chemical, pharmaceutical, and biotechnology markets are considered to provide an insight into some of the factors influencing strategic planning for 1992. This book consists of 10 chapters and opens with an overview of the EC's goal of establishing a single market for the European Union by 1992, followed by a discussion on the implications of this single market for industry, commerce, and individuals. The following chapters focus on the Single European Act; corporate issues such as mergers and acquisitions; standards of good practice in the chemical, pharmaceutical, and biotechnology sectors; and implications of a single European market for these industries. The final chapter is devoted to the views of organizations in the chemical, pharmaceutical, and biotechnology sectors such as the European Chemical Industry Federation (CEFIC), Bayer AG, and COLIPA (European Cosmetic Industry Federation) in terms of the opportunities, problems, and challenges of the single European market. This monograph will be a useful resource for corporate managers, especially those in the IT sector, as well as policymakers and industry regulators.

Download or read book Health Care Mergers and Aquisitions Answer Book 2014 written by Andrew L. Bab and published by . This book was released on 2014-08-15 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: In a fast-changing U.S. health care environment, Health Care Mergers and Acquisitions Answer Book 2014 provides the reader with a road map of how general M&A principles apply to transactions in the health care sector. Organized into four parts, it includes practical advice on how to address the various industry-specific issues arising in health care acquisitions: Part I: Structuring Health Care Transactions, focuses on the various legal and practical areas that can have an impact on the structure of a health care M&A transaction, including provisions relating to purchase price, as well as regulatory, antitrust, financing, and tax and accounting considerations. Part II: Due Diligence, discusses the regulatory and compliance issues arising in health care transactions, including compliance with the federal and state health care fraud and abuse laws, Medicare and Medicaid rules, HIPAA and other health care regulations, as well as other topics, such as intellectual property rights, material contracts, and product liability and medical malpractice claims. Part III: Transaction Documentation, analyzes the principal elements of a purchase agreement for a health care transaction, including industry-specific representations and warranties, pre- and post-closing covenants, closing conditions and indemnification provisions typically found in health care acquisition agreements. Part IV: Special Topics in Health Care M&A, covers special issues arising in acquisitions of U.S. companies by non-U.S. buyers, as well as an overview of health care M&A transactions in France, Germany and Russia. Health Care Mergers and Acquisitions Answer Book 2014 analyzes examples from recent health care transactions, and provides practice tips on what to look out for and how to avoid the various pitfalls that may be encountered while working on health care transactions. It covers deal-making involving pharmaceutical and biotech companies, hospitals, health insurers and other participants of the health care sector. In addition to transactions involving outright acquisitions of health care companies, Health Care Mergers and Acquisitions Answer Book 2014 reviews alternative structures used in health care M&A transactions, such as: joint ventures - strategic alliances - product and portfolio acquisitions - option transactions, and - licensing and collaboration agreements.

Download or read book M ergers A cquisitions in the U S pharmaceutical and biotech industries written by Yuchen Xu and published by . This book was released on 2015 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Observations of Biotech and Pharmaceutical Industry Merger and Acquisition Acquired In Process Research and Development Impairment Indicators written by Sheng-Feng Hsieh and published by . This book was released on 2016 with total page 40 pages. Available in PDF, EPUB and Kindle. Book excerpt: The Financial Accounting Standards Board (FASB) released a revised version of Statement of Financial Accounting Standards No. 141 (SFAS No. 141(R)) in December 2007. Accounting treatments of acquired in-process research and development (IPR&D) in a business combination change from expensing to capitalizing as an indefinite-life intangible asset, and need to perform annual impairment test subsequently. Combining the above changes with the thriving M&A activities trend in U.S. biotech and pharmaceutical industry, we will focus on the industry, summarize M&A transactions including acquired IPR&D capitalization happened in the period of 2009-2012 and examine the association between impairment indicators and write-offs of acquired IPR&D. Empirical results reveal that five impairment indicators are significantly correlated with acquired IPR&D impairment recognition in the sample of 98 observations. We also collect possible reasons that result in the impairment recognition.

Download or read book Mergers and Productivity written by Steven N. Kaplan and published by University of Chicago Press. This book was released on 2007-12-01 with total page 350 pages. Available in PDF, EPUB and Kindle. Book excerpt: Mergers and Productivity offers probing analyses of high-profile mergers in a variety of industries. Focusing on specific acquisitions, it illustrates the remarkable range of contingencies involved in any merger attempt. The authors clearly establish each merger's presumed objectives and the potential costs and benefits of the acquisition, and place it within the context of the broader industry. Striking conclusions that emerge from these case studies are that merger and acquisition activities were associated with technological or regulatory shocks, and that a merger's success or failure was dependent upon the acquirer's thorough understanding of the target, its corporate culture, and its workforce and wage structures prior to acquisition. Sifting through a wealth of carefully gathered evidence, these papers capture the richness, the complexity, and the economic intangibles inherent in contemporary merger activity in a way that large-scale studies of mergers cannot.